Abstract:Abstract Background Tumor-associated macrophages (TAM) are immunosuppressive cells that contribute to impaired anti-cancer immunity. Iron plays a critical role in regulating macrophage function. However, it is still elusive whether it can drive the functional polarization of macrophages in the context of cancer and how tumor cells affect the iron-handing properties of TAM. In this study, using hepatocellular carcinoma (HCC) as a study model, we aimed to explore the effect and mechanism of reduced ferrous iron in TAM. Methods TAM from HCC patients and mouse HCC tissues were collected to analyze the level of ferrous iron. Quantitative real-time PCR was used to assess M1 or M2 signature genes of macrophages treated with iron chelators. A co-culture system was established to explore the iron competition between macrophages and HCC cells. Flow cytometry analysis was performed to determine the holo-transferrin uptake of macrophages. HCC samples from The Cancer Genome Atlas (TCGA) were enrolled to evaluate the prognostic value of transferrin receptor (TFRC) and its relevance to tumor-infiltrating M2 macrophages. Results We revealed that ferrous iron in M2-like TAM is lower than that in M1-like TAM. In vitro analysis showed that loss of iron-induced immunosuppressive M2 polarization of mouse macrophages. Further experiments showed that TFRC, the primary receptor for transferrin-mediated iron uptake, was overexpressed on HCC cells but not TAM. Mechanistically, HCC cells competed with macrophages for iron to upregulate the expression of M2-related genes via induction of HIF-1α, thus contributing to M2-like TAM polarization. We further clarified the oncogenic role of TFRC in HCC patients by TCGA. TFRC is significantly increased in varieties of malignancies, including HCC, and HCC patients with high TFRC levels have considerably shortened overall survival. Also, TFRC is shown to be positively related to tumor-infiltrating M2 macrophages. Conclusions Collectively, we identified iron starvation through TFRC-mediated iron competition drives functional immunosuppressive polarization of TAM, providing new insight into the interconnection between iron metabolism and tumor immunity.

Iron TAMs: The fallen protectors

An iron-rich subset of macrophages promotes tumor growth through a Bach1-Ednrb axis

Tumor cell-imposed iron restriction drives immunosuppressive polarization of tumor-associated macrophages

The role of iron metabolism in cancer therapy focusing on tumor‐associated macrophages

Tumor-Associated Macrophages in Tumor Immunity (vol <i>11</i>, <i>583084</i>, <i>2020</i>)

Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment

Tumor Associated Macrophages Deliver Iron to Tumor Cells Via Lcn2.

Tumor associated macrophages transfer ceruloplasmin mRNA to fibrosarcoma cells and protect them from ferroptosis

Remodeling Macrophages by an Iron Nanotrap for Tumor Growth Suppression

TAM-tastic: from resistance to resilience in cancer

Tumor-Associated Macrophages and Their Functional Transformation in the Hypoxic Tumor Microenvironment

Comprehensive Proteomics Analysis Reveals Metabolic Reprogramming of Tumor-Associated Macrophages Stimulated by the Tumor Microenvironment.

Ferroptosis-Strengthened Metabolic and Inflammatory Regulation of Tumor-Associated Macrophages Provokes Potent Tumoricidal Activities

Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment

Role and Mechanisms of Tumor-Associated Macrophages in Hematological Malignancies

Tumor-Associated Macrophages as Major Immunosuppressive Cells in the Tumor Microenvironment

Tumour-associated macrophages: versatile players in the tumour microenvironment

Progress in Tumor‐Associated Macrophages: from Bench to Bedside

Roles of Tumor-Associated Macrophages in Tumor Environment and Strategies for Targeting Therapy

Iron Participated in Breast Cancer Chemoresistance by Reinforcing IL-6 Paracrine Loop

TAM-ing the CIA-Tumor-Associated Macrophages and Their Potential Role in Unintended Side Effects of Therapeutics for Cancer-Induced Anemia